α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. Read more about α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.
The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion. Read more about The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion.
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. Read more about Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas. Read more about Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas.
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). Read more about Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).
Immune oncology, immune responsiveness and the theory of everything. Read more about Immune oncology, immune responsiveness and the theory of everything.
In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series. Read more about In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series.
A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report. Read more about A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report.
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. Read more about Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. Read more about Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
